Hydroquinone, Tretinoin and Mometasone Furoate cream

Hydroquinone, Tretinoin and Mometasone Furoate Cream is a combination of mometasone furoate (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and tretinoin (a retinoid) that is indicated for the short-term treatment of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens.

Apply a thin film of Deroton Cream to the affected area once daily, at least 30 minutes before bedtime.
Gently wash the face and neck with a mild cleanser. Rinse and pat the skin dry. Apply Deroton Cream to the affected area of melasma including about 1/2 inch of normal appearing skin surrounding each lesion. Rub lightly and uniformly into the skin. Therapy should be discontinued when control is achieved.
During the day, use a sunscreen and wear protective clothing. Avoid sunlight exposure. Patients may use moisturizers and/or cosmetics during the day.
Hydroquinone, Tretinoin and Mometasone Furoate Cream is for topical use only. It is not for oral, ophthalmic, or intra vaginal use.

The following is a list of possible side effects that may occur from Deroton Cream. This is not a comprehensive list. These side effects are possible, but do not always occur. Some of the side effects may be rare but serious. Immediately the treatment should be stop, especially if they do not go away. Erythema, Desquamation, Burning, Dryness, Pruritus, Acne, Paresthesia, Telangiectasia, Hyperesthesia, Pigmentary changes, Irritation, Papules, Acne-like rash, Rosacea, Dry mouth, Rash and Vesicles.

The following local adverse reactions have been reported with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.

Cutaneous Reactions
Cutaneous hypersensitivity to the active ingredients of Deroton Cream has been reported in the literature.
Deroton Cream contains hydroquinone and tretinoin that may cause mild to moderate irritation. Local irritation, such as skin reddening, peeling, mild burning sensation, dryness, and pruritus may be expected at the site of application. Transient skin reddening or mild burning sensation does not preclude treatment. If a reaction suggests hypersensitivity or chemical irritation, the use of the medication should be discontinued.
Patients should avoid medicated or abrasive soaps and cleansers, soaps and cosmetics with drying effects, products with high concentrations of alcohol and astringents, and other irritants or keratolytic drugs while on Deroton Cream treatment. Patients are cautioned on concomitant use of medications that are known to be photosensitizing.
Effects on Endocrine System
Deroton Cream contains the corticosteroid Mometasone furoate. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria can also be produced by systemic absorption of topical corticosteroid while on treatment. If HPA axis suppression is noted, the use of Deroton Cream should be discontinued. Recovery of HPA axis function generally occurs upon discontinuation of topical corticosteroids.
Exogenous Ochronosis
Deroton Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, the occurrence of which should prompt discontinuation of therapy. The majority of patients developing this condition are Black, but it may also occur in Caucasians and Hispanics.
Hypersensitivity
Deroton Cream contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible individuals. If anaphylaxis, asthma or other clinically significant hypersensitivity reactions occur, institute appropriate therapy and discontinue Deroton. Allergic contact dermatitis may also occur.

Store below 30 °C preferably in cool and dry place. Protect from light.
Keep the medicine out of reach of children.

Lami tube with white cap containing 15 g of Cream. Such 01 tube in a monocarton with pack insert.